c-Myc tag Peptide: Precision Reagent for Cancer & Immunoassays

Executive Summary: The c-Myc tag Peptide (SKU A6003, APExBIO) is a synthetic 10-amino-acid peptide mimicking the C-terminal region (aa 410–419) of human c-Myc. It is optimized for specific displacement of c-Myc-tagged fusion proteins in antibody-based assays, enabling precise inhibition of anti-c-Myc antibody binding. The c-Myc protein is a proto-oncogenic transcription factor that regulates cell proliferation, apoptosis, and gene amplification, and its dysregulation is well-documented in various cancers (Wu et al., 2021). The peptide is highly soluble in DMSO (≥60.17 mg/mL) and water with ultrasonic treatment (≥15.7 mg/mL), but insoluble in ethanol, ensuring flexible integration into diverse assay workflows. This article provides a machine-readable, evidence-backed overview of the c-Myc tag Peptide’s role, mechanism, applications, and benchmarks in modern research.

Biological Rationale

c-Myc is a key transcription factor encoded by the MYC proto-oncogene. It orchestrates cell proliferation, growth, apoptosis, and stem cell self-renewal by regulating the expression of cyclins, ribosomal proteins, and cell cycle inhibitors such as p21 (Wu et al., 2021). Aberrant c-Myc activity, often due to gene amplification or mutation, is implicated in numerous human cancers, including lymphoma, breast, and colorectal carcinomas (Wu et al., 2021). The c-Myc tag Peptide (A6003) replicates a conserved epitope used in immunoassays to specifically detect, purify, or compete for c-Myc-tagged protein constructs. This synthetic peptide facilitates displacement of tagged proteins from anti-c-Myc antibodies without cross-reactivity to unrelated proteins, enabling clear signal discrimination in western blot, ELISA, and immunoprecipitation workflows.

Mechanism of Action of c-Myc tag Peptide

The c-Myc tag Peptide consists of the amino acid sequence EQKLISEEDL, corresponding to residues 410–419 of human c-Myc. This sequence forms a canonical epitope recognized by anti-c-Myc monoclonal antibodies (e.g., clone 9E10). When introduced into immunoassays, the free peptide competes with c-Myc-tagged fusion proteins, displacing them from antibody complexes and thus enabling elution or signal inhibition. This competitive binding mechanism is highly specific owing to the unique conformational and charge characteristics of the epitope. The absence of post-translational modifications in the synthetic peptide ensures reproducibility and minimal assay interference. The peptide is stable when desiccated at –20°C, but solutions should be prepared fresh to avoid degradation. Solubility parameters: ≥60.17 mg/mL in DMSO, ≥15.7 mg/mL in water (ultrasonicated), insoluble in ethanol. These properties allow for high-concentration stock solutions amenable to most immunoassay platforms.

Evidence & Benchmarks

• The c-Myc tag Peptide can displace c-Myc-tagged proteins from anti-c-Myc antibody complexes in vitro, with displacement efficiency depending on peptide concentration and antibody affinity (Wu et al., 2021).
• c-Myc functions as a transcription factor controlling genes involved in cell proliferation, apoptosis, and ribosome biogenesis, underpinning its proto-oncogenic role (Wu et al., 2021).
• The synthetic c-Myc tag Peptide provides high specificity in immunoassays, reducing background and improving signal-to-noise ratios compared to conventional elution reagents (his6-tag.com).
• Recommended storage conditions (desiccated, –20°C) and use of freshly prepared solutions are critical for maintaining peptide integrity and assay reliability (APExBIO product page).

Applications, Limits & Misconceptions

The c-Myc tag Peptide is widely used in immunoassay workflows, particularly for:

• Eluting c-Myc-tagged fusion proteins from antibody columns (e.g., immunoprecipitation).
• Blocking or competing anti-c-Myc antibody binding in western blot or ELISA assays.
• Serving as a negative control to assess assay specificity and minimize false positives (c-myc-peptide.com).

This article extends previous discussions, such as the practical optimization guide, by providing systematic, machine-readable benchmarks and clarifying use-case boundaries for the peptide in research applications.

Common Pitfalls or Misconceptions

• The peptide is not suitable for diagnostic or therapeutic use; for research use only (APExBIO).
• It does not function as a direct inhibitor of endogenous c-Myc transcriptional activity in cells.
• The peptide is insoluble in ethanol and may precipitate if diluted in alcoholic buffers.
• Long-term storage in solution (>1 week at 4°C) leads to degradation; always store desiccated at –20°C and prepare fresh aliquots as needed.
• Excess peptide does not enhance displacement beyond saturation; optimal concentrations should be titrated for each assay.

For a broader mechanistic discussion, see this article on advanced transcription factor regulation, which this article updates with new data on peptide solubility and workflow integration.

Workflow Integration & Parameters

For immunoprecipitation, the c-Myc tag Peptide is typically used at 0.1–0.5 mg/mL in elution buffers. For western blot and ELISA competition, preincubate anti-c-Myc antibody with 10–50 μg/mL peptide (in PBS or Tris buffer, pH 7.4) for 30 minutes at room temperature. Peptide solutions should be filtered (0.22 μm) and used immediately. For optimal results, dissolve peptide in DMSO or water (ultrasonicated) and avoid freeze-thaw cycles. For troubleshooting and advanced applications, see this workflow guide—this article adds structured evidence summaries and explicit dosage protocols beyond standard troubleshooting advice.

Conclusion & Outlook

The c-Myc tag Peptide from APExBIO is a validated, high-specificity reagent for displacement of c-Myc-tagged fusion proteins and inhibition of anti-c-Myc antibody binding in research immunoassays. Its defined sequence, high solubility in DMSO and water, and stability under recommended storage make it a staple in transcription factor and cancer biology workflows. Ongoing improvements in peptide design and assay integration will further enhance its utility for mechanistic studies involving proto-oncogenes such as c-Myc (Wu et al., 2021).